HHS Needs More Rebate Information To Negotiate Medicare Drug Prices, Say USC Experts
February 19th 2024The Health and Human Services department could wind up overpaying (or possibly underpaying) for the drugs for which it is negotiating a “maximum fair price” for Medicare under the Inflation Reduction Act, argue experts at the USC Schaeffer Center for Health Policy and Economics. A fuller picture of rebates and net prices could help that from happening, they say.
Read More
FDA Updates for the Week of Feb. 12, 2024: New Approvals, an Extended Review and Goal Dates Set
February 17th 2024The FDA approves Eohilia for eosinophilic esophagitis and Onivyde for metastatic pancreatic cancer but extends review of gene therapy for rare immune disorder. The agency also set goal dates for three products: full approval for Elevidys, Augtyro for solid tumors with NTRK gene fusions and seladelpar as for rare liver disease.
Read More
New Federal Rule Overhauls Health Insurers' Prior Authorization Processes
February 16th 2024The rule comes as health insurers have increasingly been criticized for onerous and time-consuming prior authorization procedures that physicians say unfairly delay or deny the medical treatment that their patients need.
Read More
SGLT2 Inhibitors Superior to Other Oral Diabetes Drugs for People with Type 2 Diabetes and NAFLD
February 12th 2024A large retrospective study of patients in South Korea shows that the SGLT2 inhibitors seem to do a better job with bringing about regression of nonalcoholic fatty liver disease.
Read More